Nyrada advances toward Phase 2a trial of cardioprotective candidate

November 18, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Nyrada (ASX:NYR) is progressing steadily toward the next stage of clinical development for its lead cardioprotective drug candidate, Xolatryp, with the company confirming that its Phase 2a trial remains on track to commence in March 2026. …

Subscribe now to continue reading.

Latest Video

Time to save the government from itself and its own bad habits on this program
November 17, 2025 - Latest News
We know they're planning something on these issues, because they told us
November 18, 2025 - Latest News
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - Latest News
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - Latest News
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - Latest News

Nyrada advances toward Phase 2a trial of cardioprotective candidate

This is a preview of subscriber content

Latest Video

Most Read

Time to save the government from itself and its own bad habits on this program

We know they're planning something on these issues, because they told us

The need to honour a strong history while ensuring the future is guided by the 'good guys'

Is this disconnect so entrenched we can no longer recognise the presence of a problem?

BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia

New Stories

OncoSil charts a new growth phase as Chairman outlines progress and opportunities

CSL unveils US expansion, cementing its position as a global biopharma leader

Cleo Diagnostics appoints U.S. oncologist as first key opinion leader

IDT Australia resets strategy as advanced therapies drive new phase of growth

Dimerix Phase 3 kidney trial clears seventh safety review

Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas

BCAL advances early cancer detection portfolio as Australian launch looms

Sign In

Nyrada advances toward Phase 2a trial of cardioprotective candidate

This is a preview of subscriber content

Latest Video

Most Read

Time to save the government from itself and its own bad habits on this program

We know they're planning something on these issues, because they told us

The need to honour a strong history while ensuring the future is guided by the 'good guys'

Is this disconnect so entrenched we can no longer recognise the presence of a problem?

BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia

Follow Us

New Stories

OncoSil charts a new growth phase as Chairman outlines progress and opportunities

CSL unveils US expansion, cementing its position as a global biopharma leader

Cleo Diagnostics appoints U.S. oncologist as first key opinion leader

IDT Australia resets strategy as advanced therapies drive new phase of growth

Dimerix Phase 3 kidney trial clears seventh safety review

Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas

BCAL advances early cancer detection portfolio as Australian launch looms